News and features

Professor Clare Isacke discovered that a signalling pathway in ER-positive breast cancer that is linked to resistance to aromatase inhibitors in some cancers.

Two researchers from The Institute of Cancer Research, London, have updated delegates at the UK's biggest cancer conference about the latest developments in breast cancer research.

Combining two different targeted therapies could greatly increase the effectiveness of bladder cancer treatments by blocking a tumour’s path to drug resistance, a new study reports.

An over-active gene called GNAS may help drive the growth of some types of difficult-to-treat breast cancers, ICR scientists have found.

The huge genetic diversity within tumours is threatening efforts to create personalised cancer treatments – but, as an article in Nature Biotechnology reveals, scientists at The Institute of Cancer Research in London believe powerful new technology will bring a solution.

Scientists at The Institute of Cancer Research have this week revealed promising early results from two exciting new targeted cancer drug

Scientists from the ICR's Breakthrough Breast Cancer Research Centre have become the first to fully sequence the DNA of two breast cancers caused by a faulty BRCA1 gene. Surprisingly, changes in the genetic code of the two tumours looked almost entirely different from one another.

The NCRI Cancer Conference is the UK’s major forum for showcasing the best British and international cancer research.

Scientists have uncovered a new way of killing cancer cells, opening up a potentially highly effective avenue of attack in the fight against all forms of the disease.